Navigation Links
YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
Date:3/15/2010

strategy to exploit the nanometer range Auger electrons emitted by 111In for the treatment of cancer. Nimotuzumab has the necessary specificity for breast cancer cells overexpressing EGFR that allowed us to selectively kill these cells with these ultrashort range electrons emitted by 111In."

YM is also developing its IntelliMab(TM) technology which is designed to generate novel antibodies that selectively target cancer cells while avoiding receptors found in normal tissue. This proprietary approach to the design and selection of molecules permits IntelliMab-generated antibodies to maximize anticancer activity while minimizing toxic adverse effects. IntelliMabs are promising for a number of conditions and targets as well as for conjugation to a range of highly potent toxins.

"These data will reinforce our position that antibodies with superior targeting are ideal for delivery of toxic payloads selectively to cancer cells," said Sean Thompson, Vice President of Corporate Development at YM and General Manager of the IntelliMab platform. "IntelliMabs are excellent drug candidates in their own right and should ideally be safe delivery vehicles for use with conjugation technologies. The presentation of data by Dr. Reilly's lab is an important step both for nimotuzumab and the IntelliMab platform."

The second poster pr
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 ITRA Global, one of the ... commercial real estate, has further expanded its global reach ... and Brisbane, Western Australia, reports Mylinda Vick, CCIM, Chairman ... ITRA Global / ACORPP (Australian Corporate Property and Projects) ... providing property services to a wide range of clients ...
(Date:12/19/2014)... 19, 2014 Naurex Inc., a biopharmaceutical company ... diseases of the central nervous system, today announced that ... officer, will present at the 33 rd annual ... place at 3:00 p.m. PST on Tuesday, January 13, ... San Francisco, Calif. About ...
(Date:12/19/2014)... 2014 BioPlus Specialty Pharmacy ... pharmacies, has an expanded team of Regional Pharmaceutical ... for prescriber offices in their regions, with specific ... have a variety of Regional Pharmaceutical Care Liaisons ... in hepatitis C help prescribers understand all the ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 iLab Solutions, ... the appointment of Siri Bryant as the new Director ... Director of Core Implementations. These two new leadership positions ... customer service by ensuring that iLab continues to meet ... the last four years, iLab has been deployed at ...
Breaking Biology Technology:ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2
... , SAN DIEGO, Aug. 24 ... that Mark Booth has joined the Company as Chief Commercial ... and business development experience to Orexigen. Most recently he ... he presided over the commercial, medical and scientific affairs, business ...
... NESS ZIONA, Israel, August 24 Foamix ... gynecology, announced today,that it has been awarded US Patent ... foam compositions, suitable for the,treatment of heat and chemical ... Dr. Dov Tamarkin, the Company,s CEO stated, ...
... ... , ... Surrey, British Columbia (PRWEB) August 24, 2009 -- QImaging, a leading developer and ... announced the release of the EXi Aqua Bio-imaging Microscopy Camera. This product replaces ...
Cached Biology Technology:Orexigen(R) Therapeutics Appoints Mark Booth Chief Commercial Officer 2Foamix Receives US Patent on Novel Foam Technology 2QImaging Introduces EXi Aqua™ Microscopy Camera for Bio-Imaging 2QImaging Introduces EXi Aqua™ Microscopy Camera for Bio-Imaging 3
(Date:12/10/2014)... 2014 Research and Markets ( ... "Biometrics Market in Japan 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of biometrics ... banking and upgradation of the driver,s license is ... market. Besides the aforementioned projects, biometrics is being ...
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a leading ... that its DigitalPersona ® Pro Enterprise software ... been deployed throughout First Bank branch locations in ... South Carolina and Virginia. First Bank, a ... Southern Pines, North Carolina , selected the ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... new technique that searches blood for the tiniest remnants ... how cells crank up cancer activators called proteases. The ... cancer and point to where to look for possible ... PLoS ONE , the research shows previously unknown ...
... our bodies grow, develop and interact in a highly ... invade our bodies and cause infectious disease interact with ... culturing and studying human cells have traditionally been carried ... such 2-D culturing and modeling efforts have produced a ...
... Phone calls with a peer facing the same self-management ... their blood sugar levels better than those who used ... from the University of Michigan Health System. The ... Internal Medicine, showed the peer partner program resulted ...
Cached Biology News:New clues to how cancer-related proteins plasmin, thrombin lose inhibition 2New clues to how cancer-related proteins plasmin, thrombin lose inhibition 3New clues to how cancer-related proteins plasmin, thrombin lose inhibition 4The world is not flat: Exploring cells and tissues in three dimensions 2The world is not flat: Exploring cells and tissues in three dimensions 3The world is not flat: Exploring cells and tissues in three dimensions 4Diabetic adults' conditions improved after phone calls with fellow patients 2Diabetic adults' conditions improved after phone calls with fellow patients 3
... Saccharomyces cerevisiae, as well as other yeasts, ... molecular biology laboratories. The ability to transform ... and linear DNAs using lithium based buffers ... transformations and library screening easy and reliable, ...
... jetSI-ENDO-FluoF is a ... nm; emission at 520 nm), ... These reagents are used to ... investigate the intracellular delivery and ...
... Designed specifically for high efficiency ... Low toxicity reagent proven to ... range of cell types. Results ... 95% of target gene expression. ...
... siRNA transfection reagent that has been shown ... variety of cell lines. jetSI-ENDO is serum ... protocol. High levels of gene silencing (up ... 20 to 100 nM of siRNA in ...
Biology Products: